SMTL ID : 5f4n.1

Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.91 Å

Oligo State

monomer

Ligands

2 x 5UY: methyl 6-[(5-cyanopyrazin-2-yl)amino]-4-[[(2~{R})-morpholin-2-yl]methylamino]pyridine-3-carboxylate(Non-covalent)

5UY.1: 18 residues within 4Å: Chain A: L.15, G.16, V.23, A.36, K.38, E.55, V.68, L.84, E.85, Y.86, C.87, S.88, G.90, E.91, E.134, L.137, S.147, D.148 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:L.137 Hydrogen bonds: A:L.15, A:E.85, A:C.87, A:E.91, A:D.148 Water bridges: A:E.91, A:F.149 5UY.2: 6 residues within 4Å: Chain A: W.9, A.26, V.35, V.37, Y.71, F.83 2 PLIP interactions: 2 interactions with chain A pi-Stacking: A:W.9, A:F.83

4 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.3: 3 residues within 4Å: Chain A: L.179, S.212, D.213 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:D.213, A:D.213 Water bridges: A:Q.210 EDO.4: 2 residues within 4Å: Chain A: G.123, R.156 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:G.123 Water bridges: A:R.156 EDO.5: 5 residues within 4Å: Chain A: D.209, Q.210, S.212, S.214, C.215 7 PLIP interactions: 7 interactions with chain A Hydrogen bonds: A:D.209, A:S.212, A:S.212 Water bridges: A:D.209, A:S.214, A:Q.216, A:E.217 EDO.6: 3 residues within 4Å: Chain A: L.206, W.208, D.209 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:L.206

2 x GOL: GLYCEROL(Non-functional Binders)

GOL.7: 6 residues within 4Å: Chain A: W.221, K.222, K.224, H.243, L.246, V.247 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:K.222, A:K.224, A:H.243 Water bridges: A:K.224 GOL.8: 8 residues within 4Å: Chain A: F.93, I.96, P.133, Y.173, A.200, G.204, E.205, L.206 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:Y.173, A:Y.173, A:G.204

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Osborne, J.D. et al., Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J.Med.Chem. (2016)

Release Date

2016-05-25

Peptides

Serine/threonine-protein kinase Chk1: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Serine/threonine-protein kinase Chk1